TERAPIA MEDICAMENTOSA DE ANTICONCEPCIONAIS ORAIS COMBINADOS E SUA ASSOCIAÇÃO COM SÍNDROMES METABÓLICAS

• DOI: 10.22533/at.ed.14923041213

• Palavras-chave: Contraceptivos orais combinados, Síndromes metabólicas, esteróides.

• Keywords: Combined oral contraceptives, Metabolic syndromes, steroids

• Abstract: Of the hormonal contraceptive methods available such as birth control pills, in most cases, they are the first method of choice. Due to easy administration, treatment adherence and profitability. However, like any medication, it can present significant adverse reactions and side effects, although even low doses demonstrate safety. The combined oral contraceptives (COCs) available on the market contain an estrogenic compound, mostly ethinyl estradiol, and a progestagenic component such as: levonogestrel and drospirenone, which apply in their composition and dosage and may be: first, fourth generation. They act by preventing ovulation and altering physiological characteristics of the female reproductive system such as: The hormones LH (luteinizing) and FSH (follicle stimulating) released by the pituitary gland are inhibited, the immunity of the cervical mucus and the endometrium are altered, altering the blockage of conception. The objective of this study was to analyze the background of the correlations between the use of COCs and their association with the development of metabolic syndromes. In this way, we provide greater safety and a better understanding of its use, contraindications and possible side effects in tall women and/or with comorbidities. The androgenic effects of COCs depend on the type and dosage, they can cause potential metabolic interference in the five main metabolic pathways: Protein, insulin, lipid, hemostatic and zinc. Furthermore, it was found that age, time of use, presence of comorbidities and anthropometric profile are determining factors in influencing the response to the use of COCs.